SLC2A4

Across TCGA pan-cancer cohorts, SLC2A4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC2A4 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SLC2A4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC2A4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, UCEC, and LUSC are the cancer types where SLC2A4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
UCEC	OS	Median	All	0.969	0.652	.027	16	view →
LUSC	OS	Median	III,IV	0.126	0.664	.008	12	view →
SARC	DFS	Median	All	0.006	0.611	<.001	6	view →
LIHC	DFS	Median	II,III,IV	0.079	0.429	.004	6	view →
SKCM	DFS	Median	II,III,IV	0.408	0.711	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC2A4–DLBC (OS)

Open the DLBC breakdown →